The Hidden Burden: Endocrinopathies in Adolescents after Hematopoietic Stem Cell Transplantation.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Adolescents with malignant and nonmalignant diagnoses can require hematopoietic stem cell transplantation (HSCT), with the volume increasing 5% to 10% per annum in the United States. HSCT is an established therapy for malignancies, hemoglobinopathies, bone marrow failure, inborn errors of metabolism, and immunodeficiency. Gonadotoxic-conditioning regimens, immunosuppressive agents, and glucocorticoids are essential therapies required for a successful transplant course. Secondary endocrine sequelae can occur, however, including iatrogenic adrenal insufficiency, reduced bone mineral density, medication-induced hyperglycemia, and premature ovarian insufficiency. With broader indications for HSCT use, at-risk endocrinopathies in the post-transplant period require prompt recognition and assessment, monitoring, and medical management.